New drug zanzalintinib aims to shrink thyroid tumors before surgery
NCT ID NCT06959511
First seen Oct 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This phase 2 trial tests the drug zanzalintinib given before surgery in 45 people with advanced thyroid cancer. The goal is to see if the drug can shrink tumors, making surgery more effective. Researchers will also monitor safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT TREATMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanzalintinib
What this could lead to
If successful, this could show that zanzalintinib shrinks advanced thyroid tumors before surgery, potentially improving outcomes.
What could go wrong
This is a small, early-phase trial (45 people) with no control group. The drug may not work or could cause side effects. Results may not apply to all thyroid cancers.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.